Skip to main content

José Antonio Arranz Amo

Institutions of which they are part

Postdoctoral researcher
Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT)
Vall Hebron Institut de Recerca

José Antonio Arranz Amo

Institutions of which they are part

Postdoctoral researcher
Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT)
Vall Hebron Institut de Recerca

Projects

Desarrollo de una nueva terapia de reemplazo enzimático basada en nanotecnología para la enfermedad de Parkinson: restablecimiento de la actividad glucocerebrosidasa lisosomal mediante nanoconjugación enzima-polímero de GBA (NANO-ERT).

IP: Marta Martínez Vicente
Collaborators: José Antonio Arranz Amo, Eddie Pradas Gracia, Maria Camprodon Gomez, Laura Castillo Ribelles, Clara Carnicer Cáceres, David Moreno Martinez
Funding agency: Fundación Banco Bilbao Vizcaya Argentaria
Funding: 124047.74
Reference: BBVA/INVESTIGACIO/MARTINEZ
Duration: 01/05/2020 - 30/07/2023

Enfermedades minoritarias causantes de degeneración de ganglios basales en pedriatría: implemementación combinada del análisis genómico y de biomarcadores.

IP: Belen Perez Dueñas
Collaborators: José Antonio Arranz Amo, Josefa Élida Vázquez Méndez, Alfons Macaya Ruíz, Anna Marcé Grau, Clara Carnicer Cáceres, Mireia Del Toro Riera, Ana Felipe Rucián, Amaia Lasa Aranzasti
Funding agency: Instituto de Salud Carlos III
Funding: 196020
Reference: PI18/01319
Duration: 01/01/2019 - 31/12/2022

Apolipoproteína AIb como biomarcador y diana terapéutica de la glomeruloesclerosis segmentaria y focal idiopática (GESF)

IP: Joan López Hellin
Collaborators: José Antonio Arranz Amo, Joana Sellarés Roig, Maria Teresa Salcedo Allende, Concepció Jacobs Cachá
Funding agency: Instituto de Salud Carlos III
Funding: 88935
Reference: PI14/00275
Duration: 01/01/2015 - 30/06/2018

Neurodegeneración en la cirrosis hepática: relación con el metabolismo nitrogenado y la inflamación

IP: -
Collaborators: José Antonio Arranz Amo, Xavier Nuvials Casals, Macarena Simon-Talero Horga
Funding agency: Instituto de Salud Carlos III
Funding: 215544.56
Reference: PI11/00954
Duration: 01/01/2012 - 31/03/2016

Related news

The families of the professionals had the opportunity to visit the facilities and discover how we work at the institution.

The new system, made of cellulose and chitosan, enables sustained release of docetaxel and has demonstrated antitumor activity in preclinical models of ovarian cancer and glioblastoma.

The new therapeutic strategy aims at maintaining the efficacy of thalidomide while avoiding its main systemic adverse effects.

Related professionals

David Martinez Selva

David Martinez Selva

Main researcher
Diabetes and Metabolism
Read more
Ana Maria Rodriguez Arana

Ana Maria Rodriguez Arana

Predoctoral researcher
Molecular Imaging and Therapy
Read more
Alejandro Hernández Martínez

Alejandro Hernández Martínez

Senior researcher
Reconstructive Surgery of the Locomotor System
Read more
Ana  Román Mora

Ana Román Mora

Gestió i Administració
Communication Unit
Communication Directorate
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.